Priscilla Chan and Mark Zuckerberg are cofounders and co-CEOs of the Chan Zuckerberg Initiative. Cells are key to understanding disease--yet so much about them remains unknown. We do not know, for example, how billions of biomolecules come together to act as one cell. Nor do we know how our many types of cells interact within our bodies. We have limited understanding of how cells, tissues, and organs become diseased and what it takes for them to be healthy.

It was early one morning in 1996 when Andrew Hopkins, then a PhD biophysics student at Oxford University, had a brainwave as he walked home from a late-night lab meeting. He was trying to find molecules to fight HIV and to better understand drug resistance. "I remember this idea struck me that there must be a better way to do drug discovery other than the complex and expensive way everyone was following," he says. "Why couldn't we design an automated approach to drug design that would use all the information in parallel so that even a humble PhD student could create a medicine? That idea really stuck with me. I remember almost the exact moment to this day. And that was the genesis of the idea that eventually became Exscientia."

For context, Go is a board game previously thought to require too much human intuition for a computer to succeed in, and as a result, it was a North Star for AI. Centuries ago, scientists and doctors operated largely in the dark when attempting to cure diseases and had to rely solely on their intuition. Many current and past approaches in the field relied on a single researcher or academic group's intuition for prioritizing which genes to test edit. Recently, with advances in high-throughput single-cell CRISPR sequencing methods, we are nearing the possibility of simply testing all genes simultaneously on equal footing and in various experimental scenarios. In fact, we predict that in the next 10 years, we will have an equivalent of a Move 37 against cancer: a therapy that at first may seem counterintuitive (and at which human intuition alone would not arrive) but that in the end, shocks us all and wins the game for patients.

When it comes to medicine there are constant discoveries and advancements in the field. Now with the help of machine learning algorithms, personalized medicine and predictive patient outcome has taken another step towards curing diseases. With the data collected from patients, researchers are able to study different diseases and try to find better treatments and even cures. Scientists and pharmaceutical companies are able to use bioinformatics to develop new treatments and discover cures and treatments for diseases that currently do not have them. The benefit to using so much data is the ability to determine why some drugs worked for a population versus not for others.

When it comes to medicine there are constant discoveries and advancements in the field. Now with the help of machine learning algorithms, personalized medicine and predictive patient outcome has taken another step towards curing diseases. With the data collected from patients, researchers are able to study different diseases and try to find better treatments and even cures. Scientists and pharmaceutical companies are able to use bioinformatics to develop new treatments and discover cures and treatments for diseases that currently do not have them. The benefit to using so much data is the ability to determine why some drugs worked for a population versus not for others.

When it comes to medicine there are constant discoveries and advancements in the field. Now with the help of machine learning algorithms, personalized medicine and predictive patient outcome has taken another step towards curing diseases. With the data collected from patients, researchers are able to study different diseases and try to find better treatments and even cures. Scientists and pharmaceutical companies are able to use bioinformatics to develop new treatments and discover cures and treatments for diseases that currently do not have them. The benefit to using so much data is the ability to determine why some drugs worked for a population versus not for others.

Though medical science may still be years away from growing a heart outside of the human body, the scientists at Wake Forest Institute for Regenerative Medicine (WFIRM) are getting closer every day to reproducing and perfecting many of the tissues, blood vessels and other organs of the human body. Engineering laboratory-grown organs to implant into humans is why the Wake Forest Institute for Regenerative Medicine (WFIRM) exists. After all, they were the first in the world to do it in 1999 with engineered bladder tissue. What seemed like science fiction just a few years ago is happening now at WFIRM. Touted as an international leader in translating scientific discovery into clinical therapies, the physicians and scientists at WFIRM at Wake Forest Baptist Medical Center in Winston-Salem, North Carolina are developing organs and tissues for virtually every part of the human body as they attempt to engineer more than 30 different replacement tissues and organs and to develop healing cell therapies--all with the same goal--to cure, rather than just treat, disease. "Our goal is to apply the principles of regenerative medicine to repair or replace diseased tissues and organs," Atala said.

Silicon Valley is going to war against disease, cancer, aging, and perhaps even death, with advanced computing, AI and machine learning, genomics, DNA engineering, biotech and nanotech. Tech giants and mega-rich philanthropists are spending billions to permit hacking biology all the way down to DNA, and perhaps we could see breakthroughs in only a few years. Yes! Together we can cure disease by the end of the century. Zuckerberg and his wife, physician and educator Priscilla Chan, have enlisted a "dream team" of scientific leaders to oversee a US 3-billion effort to boost basic research, Nature News reports. The Chan Zuckerberg Initiative has been launched with the goal of helping cure, prevent and manage all diseases in our children's lifetime.

Mark Zuckerberg and Priscilla Chan's philanthropic initiative will invest 3 billion over the next decade in an effort to cure and manage all diseases. Speaking at the University of California, San Francisco, Chan announced the Chan Zuckerberg Initiative's latest venture, which will start with a 600 million investment in a project called Biohub that will connect UCSF, UC Berkeley and Stanford University to develop tools to measure and treat diseases. "We believe that the future we want for our children is possible. We set a goal: Can we cure all diseases in our children's lifetime?" Chan said during the talk.

When you get right down to it, developing vaccines is about data and luck. Scientists start with a set of variables--what drugs a virus responds to, how effectively, and for whom--and then it's a whole lot of trial and error until they stumble upon a cure. One of the most exciting possibilities in medical research right now is how technology like machine learning could help researchers rapidly process those enormous sets of data, more quickly leading to cures. This is already starting to happen: In a study published Wednesday in the journal Macromolecules, researchers from IBM and Singapore's Institute of Bioengineering and Nanotechnology reveal a breakthrough that could help prevent deadly virus infections. With the help of IBM super computer Watson, they hope their finding will soon make its way into vaccines.